A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ 8 -Tetrahydrocannabivarin in Healthy Participants
- 1 September 2023
- journal article
- research article
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 8 (S1) , S71-S82
Abstract
Introduction: Tetrahydrocannabivarin (THCV) is an understudied cannabinoid that appears to have effects that vary as a function of dose. No human study has evaluated the safety and nature of effects in a wide range of THCV doses. Methods: This was a two-phase, dose-ranging, placebo-controlled trial of the Δ8 isomer of oral THCV in healthy adults. Phase 1 utilized an unblinded, single-ascending dose design (n=3). Phase 2 used a double-blind, randomized, within-participant crossover design (n=18). Participants received single acute doses of placebo and 12.5, 25, 50, 100, and 200 mg of THCV. Safety measures and subjective and cognitive effects were assessed predose and up to 8 h postdose. Results: Most adverse events (AEs; 55/60) were mild. Euphoric mood was the most common AE. The 12.5, 25, and 200 mg doses produced significantly lower minimum times to complete the digit vigilance test (ps=0.01). The 25 mg dose showed elevations on mean ratings of “energetic” at 1-, 2-, and 4-h postdose, but the maximum postdose rating for this dose did not achieve statistical significance relative to placebo ([95% confidence interval]=3.2 [−0.5 to 6.9], p=0.116). The 100 and 200 mg doses showed elevations on ratings of “feel a drug effect” and “like the drug effect.” Almost all urine drug screens (78/79) at 8 h postdose in the active THCV conditions tested positive for tetrahydrocannabinol (THC). Conclusion: All THCV doses displayed a favorable safety profile. Several THCV doses showed a preliminary signal for improved sustained attention, but the effect was not dose dependent. Though mild and not associated with impairment, THC-like effects were observed at higher THCV doses. Oral THCV-containing products could lead to positive urine drug screens for THC. ClinicalTrials.gov ID: NCT05210634.Keywords
This publication has 35 references indexed in Scilit:
- The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesityNutrition & Diabetes, 2013
- Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's diseaseBritish Journal of Pharmacology, 2011
- Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymesBritish Journal of Pharmacology, 2010
- Potency Trends of Δ9‐THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008*Journal of Forensic Sciences, 2010
- The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in miceBritish Journal of Pharmacology, 2010
- Synthetic and plant‐derived cannabinoid receptor antagonists show hypophagic properties in fasted and non‐fasted miceBritish Journal of Pharmacology, 2009
- Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoidsMedicinal Research Reviews, 2008
- The psychoactive plant cannabinoid, Δ9‐tetrahydrocannabinol, is antagonized by Δ8‐ and Δ9‐tetrahydrocannabivarin in micein vivoBritish Journal of Pharmacology, 2007
- Paced Auditory Serial-Addition Task: A Measure of Recovery from ConcussionPerceptual and Motor Skills, 1977
- Structure-Activity Relationships in Man of Cannabis Constituents, and Homologs and Metabolites of Δ9-TetrahydrocannabinolPharmacology, 1974